AstraZeneca
lung cancer | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
16 of 157
Similar slides by AstraZeneca
See diffirences between slides (animation)
Results
November 2024
factor inhibitor ophthalmology | AstraZeneca
Results
November 2024
factor inhibitor complement mediated disease | AstraZeneca
Results
November 2024
targeting complement nephrology | AstraZeneca
Results
November 2024
kidney targeted factor fusion protein nephrology | AstraZeneca
Related slides by other companies
Adagio Therapeutics
Investor Presentation
June 2023
even in primarily populations vaccine effectiveness has waned in the face of viral evolution | Adagio Therapeutics
Exscientia
Results
March 2024
elucidate phase ongoing in advanced solid | Exscientia
Neumora Therapeutics
IPO
September 2023
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
Nuvalent
Investor Presentation
May 2023
phase population heavily solid tumors | Nuvalent
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights